ACTINIUM PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $1.90 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-25.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2022-03-25
- ACTINIUM PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2021 was $1.90M, a 7.47% increase from fiscal 2020.
- ACTINIUM PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2020 was $1.77M, a 10.58% decline from fiscal 2019.
- ACTINIUM PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2019 was $1.98M, a 0.58% decline from fiscal 2018.
- ACTINIUM PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2018 was $1.99M, a 34.42% decline from fiscal 2017.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month as first filed |
|---|---|---|
| 2021-12-31 | $1.90M 10-K · filed 2022-03-25 | |
| 2020-12-31 | $1.77M 10-K · filed 2022-03-25 | |
| 2019-12-31 | $1.98M 10-K · filed 2021-03-31 | $1.97M 10-K · filed 2020-05-08 |
| 2018-12-31 | $1.99M 10-K · filed 2020-05-08 | |
| 2017-12-31 | $3.03M 10-K · filed 2019-03-15 | |
| 2016-12-31 | $141.77K 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |